Every four year, leading experts in the field of HPV research gather together in Helsinki to report and discuss the latest developments in HPV vaccine research.
In 2012 and in 2016 – many of the speakers were from the CoheaHr consortium and the preceding PreHdict consortium. The videotaped lectures can now be accessed through our website (see: publications (non-academic)).
New publication: HPV FASTER concept
FX.Bosch et al, including the CoheaHr consortium, have published an open access opinion piece in Nature Reviews Clinical Oncology: “HPV-FASTER: broadening the scope for prevention of HPV-related cancer” – a proposal for the integration of screening and vaccination programmes, including an extention of routine vaccination programmes to older women.
CoheaHr consortium well represented at the International Papillomavirus Conference in Lisbon
The 30th International Papillomavirus Conference is taking place in Lisbon, Portugal, from September 17th-21st. The CoheaHr consortium is well represented and partners actively participate as presenters, chairpersons and workshop leaders. Here, you can find a list of selected conference proceedings related to CoheaHr: HPV2015_Lisbon_CoheaHr
Media coverage of a recent publication
A recent publication in the British Medical Journal by Bogaards et al received attention from Dutch newspapers
The article presents results on the reduction in the vaccine preventable burden of cancer in men if boys are vaccinated along with girls against oncogenic human papillomavirus (HPV)
Health Technology Assessement report on HPV primary screening (Belgium)
The Belgium Health Care Knowledge Centre (KCE) is a federal scientific organisation that aims to advise policymakers on decisions relating to health care and health insurance – on the basis of scientific analysis and research.
The Health Technology Assessment (HTA) unit of KCE has recently published its report on HPV primary screening. The report can be downloaded from KCE’s website at: https://kce.fgov.be
New publication: HPV-type specific long-term risk of CIN2 and CIN3
Following a paper on the HPV-type specific long-term risk for cytological abnormalities (Elfstrom et al), the same group has now published the HPV-type specific long-term risk for CIN2 and CIN3.
In this paper they report substantial differences in risks for CIN2 and CIN3 between different oncogenic types. The highest cumulative incidence – after 14 years of follow-up, was recorded for HPV16/18/31/33 – with a cumulative incidence for CIN3+ of above 28%. The increased risk compared to HPV negative women was highest during the initial screening round – but remained high throughout follow-up. This implies that prolonged follow-up of women positive for certain HPV types may be warranted. The quantified differences of type-specific CIN risk will be useful for the development of risk-stratified screening algorithms.
Contact: joakim.dillner@ki.se
New publication: age- and type-specific high-risk HPV incidence estimates from two population-based screening trials
Age- and type-specific hrHPV incidence estimates in screen-eligible women are relevant from a public health perspective because they provide an indication of the effect of vaccination on the occurrence of screen-positives in HPV-based screening. In this recent publication, the authors present age- and type-specific incidence estimates of screen-detected hrHPV from two large population-based screening trials (POBASCAM and NTCC). In the analyses hrHPV types are grouped according to their in- or exclusion in HPV vaccines. They report decreasing age trends of hrHPV vaccine and non-vaccine type incidences and age-related differences in the vaccine-type positivity among women with incident infections. Most importantly, hrHPV infections continued to be detected in all ages and the contribution of vaccine types remained substantial.
Contact: Nienke Veldhuijzen (n.veldhuijzen@vumc.nl)
CoheaHr Consortium well represented at the International Papillomavirus Conference in Seattle, USA
The biennial International Papillomavirus conference is taking place in Seattle, USA, from wednesday August 20st untill monday August 25th. In total 736 abstracts will be presented by researchers from across the world, including 144 oral presentations, 501 printed poster presentations and 91 poster discussions. The CoheaHr consortium is well represented and partners actively participate as presenters, chairpersons and workshop leaders. Here, you can find a list of selected conference proceedings related to CoheaHr: HPV2014_Seattle_CoheaHr
New publication: Long-term HPV type-specific risks for cytological abnormalities
In this recent publication, the authors report that high-risk HPV types 16,18, 31, 33, 45, and 52 were found to contribute substantially to low-grade cytological abnormalities. The data contributing to these analyses were collected over a period of 14-years of follow-up of a nationwide randomized HPV screening trial in Sweden. The results could be useful for the design and evaluation of HPV type-specific vaccines, screening tests and clinical management algorithms.
Elfstrom KM, Smelov V, Johansson AL et al. Long-term HPV type-specific risks for ASCUS and LSIL: a 14-year follow-up of a randomized primary HPV screening trial. Int J Cancer 2014, May 20. doi: 10.1002/ijc.28984
Contact: joakim.dillner@ki.se
CoheaHr study milestone
First 100 participants enrolled!
The CoheaHr study evaluating screening options in Finnish women who were vaccinated as adolescents has enrolled 100 participants!